MNKD-501 / MannKind, Thirona Bio - LARVOL DELTA

MannKind and Thirona Bio Join Forces to Evaluate Potential Inhaled Therapy for Fibrotic Lung Diseases (GlobeNewswire) - "MannKind Corporation (Nasdaq: MNKD) and Thirona Bio, Inc. today announced that they have entered into a transaction that is intended to advance the development of a novel compound with potential for multiple indications....Under the terms of the collaboration agreement, the companies will evaluate the therapeutic potential of Thirona’s locally acting TGF-β inhibitor for the treatment of pulmonary fibrosis. MannKind will formulate FBM5712 as a dry powder formulation...'We are excited by the opportunity to evaluate FBM5712 and to assess its potential to support our pipeline ambitions.'"

Licensing / partnership • New molecule • Idiopathic Pulmonary Fibrosis